---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-099184"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2025-07-28T23:59:59+00:00"
generated_at: "2026-05-18T00:22:35.383269+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Dyne Q2 net loss $110.9M extends cash runway into Q3 2027 on $215M offering

## Summary
- Net loss $110.9M ($0.97/sh) vs $65.1M ($0.70) in Q2 2024; R&D expenses $99.2M.
- Cash $683.9M; July offering net $215.2M; Hercules $100M initial loan; runway into Q3 2027.
- DYNE-251 DMD registrational cohort enrolled (32 pts); data late 2025; potential BLA early 2026.
- DYNE-101 DM1 FDA Breakthrough Therapy; 60-pt cohort enrollment Q4 2025; data mid-2026; BLA late 2026.
- Hercules $275M senior secured loan; 5 tranches; milestones-based drawdown; final tranche subject to approval.

## SEC filing metadata
- accession: 0000950170-25-099184
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2025-07-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000095017025099184/0000950170-25-099184-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000095017025099184/dyn-20250728.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-099184
- JSON: https://secwatch.observer/filing/0000950170-25-099184.json
- Plain text: https://secwatch.observer/filing/0000950170-25-099184.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.